Illumina (ILMN) Valuation Check As Labcorp Partnership Expands In Precision Oncology

Simply Wall St.04-01

Illumina (ILMN) just expanded its collaboration with Labcorp, centering investor attention on how next generation sequencing in precision oncology might influence the company’s role in cancer testing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624321325?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-04-01 03:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624321325","market":"sg","top_or_hot":-1,"title":"Illumina (ILMN) Valuation Check As Labcorp Partnership Expands In Precision Oncology","media":"Simply Wall St.","content":"<div>\n<p>Illumina (ILMN) just expanded its collaboration with Labcorp, centering investor attention on how next generation sequencing in precision oncology might influence the company’s role in cancer testing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-as-labcorp-partnership-expands\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina (ILMN) Valuation Check As Labcorp Partnership Expands In Precision Oncology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina (ILMN) Valuation Check As Labcorp Partnership Expands In Precision Oncology\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-01 03:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-as-labcorp-partnership-expands><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Illumina (ILMN) just expanded its collaboration with Labcorp, centering investor attention on how next generation sequencing in precision oncology might influence the company’s role in cancer testing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-as-labcorp-partnership-expands\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-as-labcorp-partnership-expands","article_id":"2624321325","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-as-labcorp-partnership-expands","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624321325","pubTimestamp":1774984172,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Illumina (ILMN) just expanded its collaboration with Labcorp, centering investor attention on how next generation sequencing in precision oncology might influence the company’s role in cancer testing and broader genomic diagnostics.\nSee our latest analysis for Illumina.\nAt a share price of US$120.81, Illumina has a 1 day share price return of 2.67%, while its 30 day and year to date share price returns show declines of around 10%. This contrasts with a 52.27% 1 year total shareholder return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","ILMN":"Illumina","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓"},"translate_title":"随着Labcorp在精准肿瘤学领域的合作伙伴关系扩大，Illumina(ILMN)的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1.5},"content_text":"Illumina (ILMN) just expanded its collaboration with Labcorp, centering investor attention on how next generation sequencing in precision oncology might influence the company’s role in cancer testing and broader genomic diagnostics. See our latest analysis for Illumina. At a share price of US$120.81, Illumina has a 1 day share price return of 2.67%, while its 30 day and year to date share price returns show declines of around 10%. This contrasts with a 52.27% 1 year total shareholder return and suggests that earlier momentum has cooled recently. If this collaboration has you thinking about where genomics and AI intersect in healthcare, it could be worth scanning a wider field of opportunities through our 34 healthcare AI stocks So with Illumina trading at US$120.81, sitting at a 19% intrinsic discount and about 13% below analyst targets after years of mixed shareholder returns, is the recent pullback creating an entry point, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 11.2% Undervalued Illumina's most followed narrative places fair value at about US$136 per share, compared with the current US$120.81 price, and builds that gap using detailed cash flow, growth, and margin assumptions under a discount rate of 8.07%.  Strong and resilient growth in clinical applications especially oncology, genetic disease testing, and reproductive health continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long-term earnings visibility. Increasing adoption of next-generation sequencing for preventive healthcare and early disease detection is driving broader utilization of Illumina's platforms, particularly as clinical markets now represent over 60% of sequencing consumables. This positions the business for sustained volume and revenue growth.  Read the complete narrative. Curious what sits behind that valuation gap? This narrative leans heavily on measured revenue growth, steadier profit margins, and a future earnings multiple that still sits below many tools peers. The tension is how those ingredients combine to justify an intrinsic value above both the market price and the analyst target. Result: Fair Value of $136.05 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there is still clear risk that tighter research budgets and ongoing regulatory pressure in China could undercut the revenue and margin assumptions behind that 11.2% discount. Find out about the key risks to this Illumina narrative. Next Steps Mixed signals on value and risks so far? Take a moment to review the data for yourself, and weigh both sides with the 4 key rewards and 1 important warning sign. Looking for more investment ideas? If Illumina has caught your attention, do not stop here. Broader context from other opportunities can sharpen your judgement and help you act with more confidence.  Spot potential bargains early by checking companies that look mispriced on fundamentals through the 62 high quality undervalued stocks. Prioritise resilience by reviewing businesses with stronger financial footing using the solid balance sheet and fundamentals stocks screener (39 results). Hunt for under followed opportunities that the market may be overlooking with the screener containing 25 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624321325","isCrawlerRequest":true}